Heron Therapeutics Inc
HRTX
NASDAQ
Biotechnology
$0.34
USD
0.00 (+0.69%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $63.49M
Volume 1.8M
Revenue
$150.71M
TTM
+1.5%
YoY
Gross Margin
71%
TTM
-3.9%
YoY
Net Income
$-30.94M
TTM
-297.4%
YoY
Operating Cash Flow
$-20.26M
TTM
+7.4%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 |
|---|---|---|---|---|---|
Revenue | 38.9 | 37.2 | 38.2 | 40.6 | 34.7 |
YoY Growth | +12.2% | +3.3% | +16.5% | -0.5% | -10.8% |
Cost of Revenue | 8.5 | 9.9 | 11.9 | 11.1 | 10.6 |
Gross Profit | 30.4 | 27.3 | 26.3 | 29.5 | 24.1 |
Selling, General & Administrative | 25.0 | 26.0 | 26.9 | 25.7 | 26.5 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 27.3 | 29.0 | 30.4 | 29.4 | 28.8 |
Operating Income | 3.2 | -1.6 | -4.1 | 0.0 | -4.8 |
EBITDA | 3.7 | -1.0 | -3.5 | 0.6 | -4.2 |
Other Income / Expense | -0.5 | -0.7 | -13.4 | 4.7 | -3.3 |
Total Other Income / Expense | -0.5 | -0.7 | -13.4 | -3.0 | -3.3 |
Income Before Income Taxes | 2.6 | -2.4 | -17.5 | -3.0 | -8.1 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | 2.6 | -2.4 | -17.5 | -3.0 | -8.1 |
Consolidated Net Income / Loss | 2.6 | -2.4 | -17.5 | -3.0 | -8.1 |
Net Income Attributable to Common Shareholders | 2.6 | -2.4 | -17.5 | -3.0 | -8.1 |
Basic EPS | $0.02 | -$0.02 | -$0.10 | -$0.02 | -$0.04 |
Diluted EPS | $0.01 | -$0.02 | -$0.10 | -$0.02 | -$0.04 |
Basic Shares Outstanding | 153.5M | 154.0M | 170.3M | 189.0M | 189.6M |
Diluted Shares Outstanding | 196.9M | 154.0M | 170.3M | 145.5M | 189.6M |